Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus Apatinib and Mitotane in Advanced ACC
NCT06831175Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in adrenocortical carcinoma (ACC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective Response Rate at 24 months. Started Mar 2025; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT06831175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06831175.